A Retrospective Cohort Study on the Impact of Oxytocin and Carbetocin on Trend of Blood Transfusion Needs Following Caesarean Delivery
Authors
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Objective: To analyze the 10-year impact of carbetocin and oxytocin on trend of blood transfusion needs during Caesarean, in University of Port Harcourt Teaching Hospital (UPTH). Design: Retrospective 10-year analysis. Subjects: 5,684 women who had Caesarean. Methods: Ethical clearance secured, a ten-year analysis of all Caesarean-related blood loss and transfusions was conducted from 1st January, 2015 to 31st December, 2024. Data were obtained from Obstetric theatre, Recovery room, Postnatal ward, Intensive care unit, and Obstetric Anaesthesia Unit records in UPTH. Results: Out of 5684 Caesarean 3427 had oxytocin and 2257 received carbetocin for third stage management. Mean blood loss [range: 699.2 (207.7) - 706.9 (218.1) versus 437.2 (112.8) - 576.7 (167.1)], proportion (%) of parturients who had blood loss >1000ml (range: 4.5 – 6.9 versus 0.0 – 3.6), needed transfusion (range: 4.1 – 7.7 versus 1.1 – 2.9), and required additional uterotonic (42.95 versus 9.39) were greater with oxytocin compared to carbetocin. With carbetocin fewer parturients experienced bradycardia (2) and hypotension (33) compared to 9 and 550 respectively, following oxytocin administration. Conclusion: There was greater reduction in Caesarean-related blood loss, transfusion, additional uterotonic use, bradycardia and hypotension, with carbetocin administration compared to oxytocin.
##plugins.themes.bootstrap3.article.details##
Copyright (c) 2025 Alfred Tamunoigbanibo Aggo, Fiekabo Hart, Sotonye Fyneface-OganGAN
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons License All articles published in Annals of Medicine and Medical Sciences are licensed under a Creative Commons Attribution 4.0 International License.
Alfred Tamunoigbanibo Aggo, Consultant, Obstetric Anaesthesia Unit, Department of Anaesthesia, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria.
Consultant, Obstetric Anaesthesia Unit, Department of Anaesthesia, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria.
Fiekabo Hart, Consultant, Obstetric Anaesthesia Unit, Department of Anaesthesia, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria.
Consultant, Obstetric Anaesthesia Unit, Department of Anaesthesia, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria.
Sotonye Fyneface-OganGAN, Professor, Obstetric Anaesthesia Unit, Department of Anaesthesia, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria.
Professor, Obstetric Anaesthesia Unit, Department of Anaesthesia, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria.
[1] World Health Organization. Maternal mortality. Available at: https://www.who.int.news-room/fact-sheets/detail/maternal-mortality. Accessed 18th February 2025.
[2] Chen Y, Chen S, Hsieh T, Lo L, Hung T A. Comparison of the efficacy of carbetocin and oxytocin on haemorrhage-related changes in women with caesarean deliveries for different indications. Taiwan J Obstet Gynecol. 2018; 57(5): 677–682. doi: 10.1016/j.tjog.2018.08.011.
[3] American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum haemorrhage. Obstet Gynecol. 2006;108(4):1039–1047. doi: 10.1097/00006250-200610000-00046.
[4] Oyelese Y, Ananth CV. Postpartum hemorrhage: epidemiology, risk factors, and causes. Clin Obstet Gynecol. 2010;53(1):147–156. doi: 10.1097/GRF.0b013e3181cc406d.
[5] Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev. 2012;2:CD005457.doi: 10.1002/14651858.CD005457.pub3. Update in: Cochrane Database Syst Rev. 2012;4: CDOO5457.doi: 10.1002/14651858.CD005457.pub4.
[6] WHO guidelines for the management of postpartum haemorrhage and retained placenta. Geneva: World Health Organization; 2009.Available at: https://who.int/iris/bitstream/handle/10665/44171/9789241598514_eng.pdf Accessed: 18th February, 2025
[7] Mohamed HF, Mustafa GF, Ibrahim MA. Stefanos GE. Comparative Study between Intravenous Bolus Dose of Carbetocin versus Oxytocin during Caesarean Delivery in Healthy Parturient on Blood Loss: A Randomized Control Trial. Med J Cairo. 2015;83:167-172.
[8] Larciprete G, Montagnoli C, Frigo M, Panetta V, Todde C, Zuppani, B, et al. Carbetocin versus oxytocin in Caesarean section with high risk of postpartum haemorrhage. J Prenat Med. 2013;7(1):12-18
[9] Sweeney G, Holbrook AM, Levine M, Yip M, Alfredsson K, Cappi S, et al. Pharmacokinetics of carbetocin, long-acting oxytocin analogue, in nonpregnant women. Curr Ther Res. 1990; 47(3):528-540.
[10] Seow K-M, Ken K-H, Wang P-H, Lin Y-H, Hwang J-L. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in infertile women with twin pregnancy undergoing Caesarean delivery. Taiwan J Obstet Gynecol 2017;56(3):273-275.doi:10.1016/j.tjog.2017.04.001
[11] Boucher M, Horbay GL, Griffin P, Deschanps Y, Desjardins C, Schuz M, et al. Double-blind, randomized comparison of the effect of carbetocin and oxytocin on intraoperative blood loss and uerine tone of patients undergoing Caesarean section. J Perinatol 1998;18:202-207
[12] Maged AM, El-Goly NA, Turki D, Bassiouny N, El-Dimiry N. A systematic review and meta-analysis of randomized trials comparing carbetocin to oxytocin in prevention of postpartum hemorrhage after Cesarean delivery in low-risk women. J Obstet Gynecol Res. 2024;51(1):e16194. doi: 10.1111/jog.16194
[13] Voon HY, Suharjono HN, Shafie AA, Bujang MA. Carbetocin versus oxytocin for the prevention of postpartum hemorrhege: A meta-analysis of randomized contrails in Cesarean deliveries. T J Obstet Gynecol 2018;57(3):332-339. doi: 10.1016/j.tlog.2018.04.002
[14] Hunter DJ, Schulz P, Wassenaar W. Effect of carbetocin, a long-acting oxytocin analog on the postpartum uterus. Clin Pharmacol Ther. 1992;52(1):60-62) and (Ref=Sweeny G, Holbrook AM, Levine M, Yip M, Alfredsson K, Cappi S, et al. Pharmakinetics of carbetocin- a long-acting oxytocin analogue, in non-pregnant women. Curr Ther Res. 1990;47(3):528-540
[15] Rath W. Prevention of postpartum hemorrhage with the oxytocin analogue carbetocin. Euro J Obstet Gynecol Reprod Biol. 2009;147(1):15-20. doi: 10.1016/j.ejogrb.2009.06.018
[16] Malm M, Madsen I, Kjellstro J. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum hemorrhage for use in low and middle-income countries. J Pept Sci. 2018;24(6):e3082. doi: 10.1002/psc.3082
[17] Onwochei DN, Van Ross J, Singh PM, Salter A, Monks DT. Carbetocin reduces the need for additional uterotonics. in elective Caesarean delivery: a systematic review, meta-analysis and trial sequential analysis of randomized controlled trials. Int J Obstet Anesth. 2019;40:14-23.doi: 10.1016/j/ijoa.2019.06.007
[18] Gutkowska J, Jankowski M, Lambert C, Mukaddam-Daher S, Zingg HH, McCann SM. Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart; evidence for oxytocin receptors in the heart. Proc Nat Acad Sci USA. 1997;94(21):11704-11709.doi: 10.1073/pnas.94.21.11704
[19] Gill P, Patel A, Van Hook JW. Uterine Atony. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih,gov/books/NBK493238/.
[20] Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017;130(4):e168-e186. doi: 10.1097/AOG.0000000000002351.
[21] Jansen AJ, van Rhenen DJ, Steegers EA, Duvekot JJ. Postpartum haemorrhage and transfusion of blood and blood components. Obstet Gynecol Surv.2005;60(10:663-671. doi: 10.1097/01.ogx.0000180909.31293.cf.
[22] World Health Organization. Active management of the third stage of labour. WHO Geneva 2007. Available at: https://www.afro.who.int/sites/default/files/2017-06/WHO_MPS_0706_engPPH.pdfAccessed: 18th February, 2025
[23] Gulmezoglu AM et al. Active management of the third stage of labour with and without controlled cord traction: a randomized, controlled non-inferiority trial. Lancet 2012.doi: 10.1016/S0140-6736(12)60206-2.
[24] World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. WHO: Geneva; 2012.Available at: https://www.iris.who.int/handle/10665/75411 Accessed: 20th February, 2025
[25] WHO recommendations: uterotonics for the prevention of PPH. WHO: Geneva 2018. Available at: https:// www.who.int/publications/i/item/9789241550420 Accessed: 20th February, 2025
[26] Lash GE. Molecular Cross-Talk at the Foeto-Maternal Interface. Cold Spring Harb Perspect Med. 2015;5(12):a023010.doi: 10.1101/cshperspect.a023010.
[27] Dobiesz VA, Robinson DW. Trama in Pregnancy. In: Walls RM, Hockgerger R, Gausche-Hill M, eds. Rosen’s emergency medicine: concepts and clinical practice. 9th ed. Philadelphia: Elsevier, 2017:2314-2322
[28] Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequencies of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009;30(6):473-482. doi: 10.1016/j.placenta.2009.02.009
[29] Levi M. Diseminated intravascular coagulation (DIC) in pregnancy and the peripartum period. Throm Res. 2009;123(2):S64-64.doi: 10.1016/S0049-3848(09)70013-1